Previous 10 | Next 10 |
Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will participate in this month’s Healthcare Virtual Conference presented by Maxim Group LLC. The three-day online event is scheduled for June 20–22, 2023, and will be hosted on the M-Vest platform. Vistagen is a late clinical-sta...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received notification that the European Patent O...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to gr...
2023-06-09 10:07:38 ET Gainers: Sientra ( SIEN ) +65% . ContraFect ( CFRX ) +47% . Societal CDMO ( SCTL ) +20% . Akili ( AKLI ) +14% . Erasca ( ERAS ) +12% . Losers: Elevation Oncology ( ELEV ) -41% . Longboar...
Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that PH80, one of the company’s five inves...
2023-06-07 09:46:39 ET Vistagen ( NASDAQ: VTGN ) announced Wednesday that its nasal spray therapy PH80 led to a statistically significant efficacy compared to placebo in a mid-stage real-world study as an acute therapy for hot flashes. Citing data from an exploratory Phase 2A st...
PH80 nasal spray demonstrates statistically significant efficacy versus placebo in exploratory double-blind, placebo-controlled Phase 2A study (n=36) in women diagnosed with menopausal hot flashes PH80 was safe and well-tolerated with an adverse event profile similar to placebo ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and ho...
2023-06-06 11:33:12 ET Vistagen ( NASDAQ: VTGN ) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023. The primary corporate and strategic objectives for reverse split is to re...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...